Swiss-based biopharmaceutical group, Debiopharm Group, Friday announced the launching of prostate cancer drug Pamorelin LA in India by Indian pharma major Dr. Reddy's Laboratories (RDY).
Pursuant to the agreement, the Indian company has exclusive marketing and sales right for the drug that will be made available to urologists and oncologists in particular.
Commenting on the development Rolland-Yves Mauvernay, President and founder of Debiopharm Group said, "This major step enables us to implement our strategy in one of the most important markets in Asia."
The drug has been launched for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer.
For comments and feedback: editorial@rttnews.com